KRT18P6

Across TCGA pan-cancer cohorts, KRT18P6 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of KRT18P6’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where KRT18P6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT18P6 is over-expressed in tumor, although a few such as BLCA and LUSC show the opposite, repressed pattern.

STAD, BRCA, and LIHC are the cancer types where KRT18P6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.055	<.001	6	view →
BRCA	All	All	+0.020	.001	6	view →
LIHC	All	II,III,IV	+0.022	.012	5	view →
HNSC	Male	II,III,IV	+0.017	.019	4	view →
PRAD	All	All	+0.032	.002	2	view →
BLCA	All	All	−0.016	.047	2	view →
LUAD	Female	All	+0.025	.045	1	view →
KICH	All	II,III,IV	+0.022	.048	1	view →
LUSC	Female	All	−0.018	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

KRT18P6–STAD

Open the STAD breakdown →